HMD Stock Overview
Develops, manufactures, and sells heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HeraMED Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.014 |
| 52 Week High | AU$0.09 |
| 52 Week Low | AU$0.013 |
| Beta | -0.063 |
| 1 Month Change | -22.22% |
| 3 Month Change | -22.22% |
| 1 Year Change | -80.56% |
| 3 Year Change | -93.78% |
| 5 Year Change | -94.72% |
| Change since IPO | -92.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| HMD | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -6.7% | -2.0% | 1.5% |
| 1Y | -80.6% | 15.2% | 8.7% |
Return vs Industry: HMD underperformed the Australian Medical Equipment industry which returned 15.2% over the past year.
Return vs Market: HMD underperformed the Australian Market which returned 8.7% over the past year.
Price Volatility
| HMD volatility | |
|---|---|
| HMD Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 10.3% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: HMD's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine HMD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Anoushka Gungadin | www.hera-med.com |
HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. It also provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus’ heartbeat; and HeraCARE, a cloud-based remote maternity care platform. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform.
HeraMED Limited Fundamentals Summary
| HMD fundamental statistics | |
|---|---|
| Market cap | AU$4.95m |
| Earnings (TTM) | -AU$6.76m |
| Revenue (TTM) | AU$604.63k |
8.2x
P/S Ratio-0.7x
P/E RatioIs HMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HMD income statement (TTM) | |
|---|---|
| Revenue | US$402.90k |
| Cost of Revenue | US$160.96k |
| Gross Profit | US$241.94k |
| Other Expenses | US$4.74m |
| Earnings | -US$4.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 60.05% |
| Net Profit Margin | -1,117.60% |
| Debt/Equity Ratio | 38.1% |
How did HMD perform over the long term?
See historical performance and comparison